BeOne Medicines (ONC) Gains from Sales and Divestitures (2016 - 2017)
Historic Gains from Sales and Divestitures for BeOne Medicines (ONC) over the last 3 years, with Q4 2017 value amounting to $268750.0.
- BeOne Medicines' Gains from Sales and Divestitures rose 50467.99% to $268750.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $268750.0, marking a year-over-year increase of 50467.99%. This contributed to the annual value of $268750.0 for FY2017, which is 50467.99% up from last year.
- As of Q4 2017, BeOne Medicines' Gains from Sales and Divestitures stood at $268750.0, which was up 50467.99% from $44445.0 recorded in Q4 2016.
- In the past 5 years, BeOne Medicines' Gains from Sales and Divestitures registered a high of $533333.0 during Q4 2015, and its lowest value of $44445.0 during Q4 2016.
- For the 3-year period, BeOne Medicines' Gains from Sales and Divestitures averaged around $282176.0, with its median value being $268750.0 (2017).
- In the last 5 years, BeOne Medicines' Gains from Sales and Divestitures tumbled by 9166.66% in 2016 and then soared by 50467.99% in 2017.
- Quarter analysis of 3 years shows BeOne Medicines' Gains from Sales and Divestitures stood at $533333.0 in 2015, then crashed by 91.67% to $44445.0 in 2016, then soared by 504.68% to $268750.0 in 2017.
- Its Gains from Sales and Divestitures stands at $268750.0 for Q4 2017, versus $44445.0 for Q4 2016 and $533333.0 for Q4 2015.